Telmisartan or Valsartan Alone or in Combination with Hydrochlorothiazide: A Review

REFERENCES

• MacMahon S, Peto R, Cutler J, . Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765–774.
   PubMed Web of Science ®Google Scholar
• Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000; 356:1955–1964.
   Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755–1762.
   Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002; 288:2981–2997.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022–2031.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, . The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. J Am Med Assoc 2003; 289:2560–2572.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, . 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6):1105–1187.
   PubMed Web of Science ®Google Scholar
• Meredith PA. Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers. Blood Press 2001; 10(Suppl. 3):11–17.
   Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995–1003.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667–1675.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851–860.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, . Telmisartan ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547–1559.
   PubMed Web of Science ®Google Scholar
• NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1477–1490.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Julius S, Mancia G, VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24:1405–1412.
   PubMed Web of Science ®Google Scholar
• Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006; 66:51–83.
   PubMed Web of Science ®Google Scholar
• Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002; 62:1983–2005.
   PubMed Web of Science ®Google Scholar
• Maillard MP, Perregaux C, Centeno C, . In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002; 302:1089–1095.
   PubMed Web of Science ®Google Scholar
• Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25:41–46.
   PubMedGoogle Scholar
• Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28:149–167.
   PubMed Web of Science ®Google Scholar
• Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res 2009; 37:1–18.
   PubMedGoogle Scholar
• Neutel JM, Smith DH. The circadian pattern of blood pressure: cardiovascular risk and therapeutic opportunities. Curr Opin Nephrol Hypertens 1997; 6:250–256.
   PubMed Web of Science ®Google Scholar
• White WB. Circadian variation of blood pressure: clinical relevance and implications for cardiovascular chronotherapeutics. Blood Press Monit 1997; 2:47–51.
   PubMedGoogle Scholar
• Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16:1123–1132.
   PubMed Web of Science ®Google Scholar
• Bakris G. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens 2002; 4(Suppl. 1):26–31.
   Google Scholar
• White WB, Lacourcière Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Am J Hypertens 2004; 17:347–353.
   PubMed Web of Science ®Google Scholar
• Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004; 22:837–846.
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Krzesinski J-M, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9:203–210.
   PubMed Web of Science ®Google Scholar
• Yano Y, Hoshide S, Ishikawa J, . The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am J Hypertens 2007; 20:565–572.
   PubMed Web of Science ®Google Scholar
• Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007; 46:1331–1336.
   PubMed Web of Science ®Google Scholar
• Hong SJ, Shim WJ, Choi JI, . Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol 2007; 100:1625–1629.
   PubMed Web of Science ®Google Scholar
• Tomiyama H, Yamada J, Koji Y, Shiina K, Yoshida M, Yamashina A. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. Am J Hypertens 2007; 20:1305–1311.
   PubMed Web of Science ®Google Scholar
• Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23:3174–3183.
   PubMed Web of Science ®Google Scholar
• Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15:942–954.
   PubMed Web of Science ®Google Scholar
• White WB, Punzi HA, Murwin D, Koval SE, Davidai G, Neutel JM. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. J Clin Hypertens (Greenwich) 2006; 8:626–633.
   PubMedGoogle Scholar
• Sharma AM, Davidson J, Koval S, Lacourcière Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH® study. Cardiovasc Diabetol 2007; 6:28.
   PubMed Web of Science ®Google Scholar
• White WB, Murwin D, Chrysant SG, Koval SE, Davidai G, Guthrie R. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press Monit 2008; 13:21–27.
   PubMed Web of Science ®Google Scholar
• White WB, Davidai G, Schumacher H. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. J Hum Hypertens 2009; 23:817–825.
   PubMed Web of Science ®Google Scholar
• Fagard R, Staessen J, Thijs L, Amery A. Multiple standardized clinic blood pressures may predict left ventricular mass as well as ambulatory monitoring. Am J Hypertens 1995; 8:533–540.
   PubMed Web of Science ®Google Scholar
• Hansen KW, Christensen CK, Anderson PH, Pedersen MM, Christiansen JS, Mogensen CE. Ambulatory blood pressure in microalbuminuric type 1 diabetic patients. Kidney Int 1992; 41:847–854.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Porcellati C, Schillaci G, . Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793–801.
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527–1535.
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903–1913.
   PubMed Web of Science ®Google Scholar
• Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155:701–709.
   PubMed Web of Science ®Google Scholar